🚀
Enjoy a 7-Day Free Trial Thru May 02, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Aptevo Therapeutics Inc (NAS:APVO)
News
Aptevo Therapeutics Inc
NAS
:APVO (USA) Â
$ 0.68
-0.0536 (-7.28%)
04:00 PM EST
P/E:
At Loss
P/B:
0.02
Market Cap:
$ 1.10M
Enterprise V:
$ -10.32M
Volume:
567.39K
Avg Vol (2M):
400.22K
Warning! GuruFocus detected 1 Severe warning sign with APVO.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
567.39K
Market Cap $:
1.10M
PE Ratio:
At Loss
Avg Vol (2M):
400.22K
Enterprise Value $:
-10.32M
PB Ratio:
0.02
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Aptevo Therapeutics Inc (NAS:APVO) Stock News, Headlines & Updates
Aptevo Therapeutics Inc Stock News from GuruFocus
Total 75
1
2
Apr 16, 2024
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
ACCESSWIRE
•
7:00pm
Apr 11, 2024
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
ACCESSWIRE
•
11:00am
Apr 10, 2024
Aptevo Therapeutics Provides Pipeline Update
ACCESSWIRE
•
11:00am
Mar 18, 2024
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
ACCESSWIRE
•
7:00am
Mar 07, 2024
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
ACCESSWIRE
•
11:00am
Mar 05, 2024
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
ACCESSWIRE
•
11:00am
Mar 04, 2024
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
ACCESSWIRE
•
11:00am
Dec 28, 2023
Thinking about buying stock in Fusion Pharmaceuticals, Aptevo Therapeutics, Blink Charging, Ampio Pharmaceuticals, or Bitcoin Depot?
PRNewswire
•
9:00am
Nov 01, 2023
Aptevo to Present at Bio-Europe Conference
ACCESSWIRE
•
7:00am
Aug 10, 2023
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
ACCESSWIRE
•
11:00am
Thinking about buying stock in Mogo Inc, Rigetti Computing, Aptevo Therapeutics, Milestone Pharmaceuticals, or Wheels Up Experience?
PRNewswire
•
9:00am
Aug 05, 2023
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
ACCESSWIRE
•
7:00pm
Aug 02, 2023
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
ACCESSWIRE
•
11:00pm
Jul 18, 2023
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
ACCESSWIRE
•
11:00am
Jul 16, 2021
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
ACCESSWIRE
•
11:00am
Jun 30, 2021
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
ACCESSWIRE
•
11:00am
Jun 29, 2021
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
ACCESSWIRE
•
11:00am
May 27, 2021
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
ACCESSWIRE
•
11:00am
May 26, 2021
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
ACCESSWIRE
•
11:00am
May 18, 2021
Aptevo Therapeutics Stock Is Believed To Be Significantly Overvalued
GF Value
•
8:12pm
May 11, 2021
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
ACCESSWIRE
•
11:00am
Feb 10, 2021
Aptevo Confirms Receipt of Nominations and Proposal Notice
ACCESSWIRE
•
6:59pm
Dec 02, 2020
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
ACCESSWIRE
•
11:00am
Nov 20, 2020
Aptevo Confirms Receipt of Unsolicited Indication of Interest
ACCESSWIRE
•
7:00pm
Nov 16, 2020
Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
ACCESSWIRE
•
11:00am
Nov 09, 2020
Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
ACCESSWIRE
•
11:00am
Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
ACCESSWIRE
•
7:00am
Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
ACCESSWIRE
•
11:00pm
Nov 03, 2020
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
ACCESSWIRE
•
11:00am
Sep 01, 2020
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
ACCESSWIRE
•
11:00am
Aug 06, 2020
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust
ACCESSWIRE
•
11:00am
Jul 21, 2020
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones
ACCESSWIRE
•
11:00am
Jun 29, 2020
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
ACCESSWIRE
•
11:00am
Jun 25, 2020
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar
ACCESSWIRE
•
11:00am
Jun 10, 2020
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
hollywood1450
•
11:00am
May 13, 2020
Aptevo Therapeutics Reports First Quarter 2020 Financial Results
hollywood1450
•
11:00am
Apr 14, 2020
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements
hollywood1450
•
11:00am
Mar 25, 2020
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update
hollywood1450
•
11:00am
Mar 16, 2020
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
hollywood1450
•
11:00am
Feb 28, 2020
Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million
hollywood1450
•
11:00am
Total 75
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news